Journal of International Oncology››2014,Vol. 41››Issue (8): 692-696.doi:10.3760/cma.j.issn.1673-422X.2014.09.015
Previous ArticlesNext Articles
Hao Furong, Lyu Chunyan, Wang Jinpeng, Wang Peihe, Li Yong, Ma Ruizhong, Wang Mingchen
Online:
2014-09-25Published:
2014-09-05Contact:
Wang Mingchen E-mail:flk2291@163.comHao Furong, Lyu Chunyan, Wang Jinpeng, Wang Peihe, Li Yong, Ma Ruizhong, Wang Mingchen. Dosage studies on simplified inverse intensity modulated radiotherapy in patients with early-stage breast cancer after breastconserving surgery[J]. Journal of International Oncology, 2014, 41(8): 692-696.
[1] Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15year survival: an overview of the randomized trials[J]. The Lancet, 2005, 366(9503): 2087-2106. [2] 张勇乾, 王雅棣. 乳腺癌保乳术后加速部分乳腺照射研究进展[J]. 中国肿瘤临床, 2013, 40(3): 178-181. [3 ] Hwang ES. Breast conservation: is the survival better for mastectomy?[J]. J Surg Oncal, 2014, 110(1): 58-61. [4] Benson JR, Jatoi I, Keisch M, et al. Early breast cancer[J]. Lancet, 2009, 373(9673): 1463-1479. [5] 尤金强, 王平. 放射治疗在早期乳腺癌中的应用[J]. 中国肿瘤临床, 2009, 36(16): 957-960. [6] 李永恒, 徐博, 徐晓娜, 等. 早期乳腺癌保乳术后全乳腺调强放疗的临床分析[J]. 中华放射医学与防护杂志, 2009, 29(1): 74-77. [7] 郑亚琴, 邢晓汾, 马永强, 等. 快速旋转调强与五野动态调强在乳腺癌保乳术后放疗中的剂量学比较[J]. 中华放射医学与防护杂志, 2013, 33(3): 282-285. [8] 孙涛, 卢洁, 尹勇, 等. 乳腺癌保乳术后正向与逆向调强放疗计划的比较[J]. 中华放射医学与防护杂志, 2009, 29(4): 401-404. [9] 周晓琳, 范秋虹, 钱建军, 等. 乳腺癌保乳术后静态逆向调强与三维适形野中野放疗的剂量学比较[J]. 中华放射医学与防护杂志, 2011, 31(6): 675-679. |
[1] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[2] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[3] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[4] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[5] | Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer: present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58. |
[6] | Wang Jing, Xu Wenting.Value of NLR, CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526. |
[7] | Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531. |
[8] | Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456. |
[9] | Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462. |
[10] | Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356. |
[11] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367. |
[12] | Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240. |
[13] | Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149. |
[14] | Li Lixi, Zhang Di, Luo Yang, Ma Fei.Clinical application of PARP inhibitors in breast cancer[J]. Journal of International Oncology, 2023, 50(2): 91-96. |
[15] | Li Jinzhi, Zhao Biao, Wen Xiaobo, Zhang Ming, Yuan Meifang, Sun Mengzhen, Pu Qin, Yang Yi.The effects of different dose calculation grid size by Monaco planning system on the dosimetry of T4nasopharyngeal carcinoma[J]. Journal of International Oncology, 2023, 50(11): 641-649. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||